Abstract:Protein homeostasis is the basis of normal life activities, and the proteasome family plays an extremely important function in this process. The proteasome 20S is a concentric circle structure with two α rings and two β rings overlapped. The proteasome 20S can perform both ATP-dependent and non-ATP-dependent ubiquitination proteasome degradation by binding to various subunits (such as 19S, 11S, and 200PA), which is performed by its active subunit β1, β2, and β5. The proteasome can degrade misfolded, excess proteins to maintain homeostasis. At the same time, it can be utilized by tumors to degrade over-proliferate and unwanted proteins to support their growth. Proteasomes can affect the development of tumors from several aspects including tumor signaling pathways such as NF-κB and p53, cell cycle, immune regulation, and drug resistance. Proteasome-encoding genes have been found to be overexpressed in a variety of tumors, providing a potential novel target for cancer therapy. In addition, proteasome inhibitors such as bortezomib, carfilzomib, and ixazomib have been put into clinical application as the first-line treatment of multiple myeloma. More and more studies have shown that it also has different therapeutic effects in other tumors such as hepatocellular carcinoma, non-small cell lung cancer, glioblastoma, and neuroblastoma. However, proteasome inhibitors are not much effective due to their tolerance and singleness in other tumors. Therefore, further studies on their mechanisms of action and drug interactions are needed to investigate their therapeutic potential.

Inhibitors of Proteasome: Research Progress

Clinical and Marketed Proteasome Inhibitors for Cancer Treatment

Advances of study of protein-protein interactions

Recent advances and future perspectives of noncompetitive proteasome inhibitors

Proteasome dysregulation in human cancer: implications for clinical therapies

Proteases and Their Modulators in Cancer Therapy: Challenges and Opportunities

The role of proteasomes in tumorigenesis

Progress of research on the ubiquitin-proteasome system and its non-degradation function

Proteasome activation: A novel strategy for targeting undruggable intrinsically disordered proteins

Targeted Protein Degradation: Principles, Strategies, and Applications

Synthesis, Bioactivity, Docking and Molecular Dynamics Studies of Furan‐Based Peptides As 20S Proteasome Inhibitors

Advances in the Development Ubiquitin-Specific Peptidase (USP) Inhibitors

Progress of small molecules for targeted protein degradation: PROTACs and other technologies

Proteomics of Proteasome Complexes and Ubiquitinated Proteins

Targeted Protein Degradation: Principles and Applications of the Proteasome

Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors

Regulation of Proteasome Activity by (Post-)transcriptional Mechanisms

Bortezomib in cancer therapy: Mechanisms, side effects, and future proteasome inhibitors

Targeted protein degradation: mechanisms, strategies and application

Proteasomal and Lysosomal Degradation for Specific and Durable Suppression of Immunotherapeutic Targets

Targeting Lysosomal Degradation Pathways: New Strategies and Techniques for Drug Discovery